Coenzyme Q10 for Statin-associated Myalgia
A popular theory holds that statins deplete coenzyme Q10, but the most rigorous pooled trials show CoQ10 supplements do not reliably reduce statin-associated muscle pain or lower muscle-enzyme (creatine kinase) levels. At best it is a low-risk option to try, not a proven treatment, and it is no substitute for adjusting or switching the statin under a doctor's care.
Why this grade7-layer evidence engine
This claim is graded counter-evidence because the most rigorous trial syntheses point against benefit. The two strongest, Cochrane-style meta-analyses are null: Kennedy 2020 (PMID 32179207, n=321) found no significant pain relief over placebo (WMD -0.42, p=0.43) and no improvement in statin adherence, and Qu 2021 (PMID 33999383, n=472) found neither pain relief nor any drop in creatine kinase (p=0.84). Because CK does not move, the core mechanistic story, that replacing statin-depleted CoQ10 should repair muscle, is not borne out as measurable benefit.
The evidence is not uniformly negative, which keeps the conclusion measured rather than dismissive. A 2024 narrative review (PMID 39350827) and an updated 2025 meta-analysis (PMID 41158831, n=389) reported benefit, the latter reaching modest significance (WMD -0.96, p=0.04). But its confidence interval nearly touches zero, only 4 of 7 trials were positive, and the authors themselves call for more rigorous studies. The large effect in an observational study (PMID 41122613, n=106) carries a high risk of bias and cannot establish cause.
Regulators and major clinics echo the cautious read. EFSA concluded a cause-and-effect relationship has not been established for CoQ10's claimed effects, and the FDA does not recognize it as a proven treatment for any disease. The Cleveland Clinic calls the evidence mixed, the National Lipid Association says there is insufficient evidence to recommend routine use, and the Mayo Clinic notes benefit shows up mainly in open-label settings, hinting at a placebo (nocebo) effect rather than a true drug action.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.46
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (4 negative > 0 positive)，下層 RCT 不能推翻
- apply_hec_override — HEC-1 高階證據 negative — 強制由 C 改為 D
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status